This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bionano Genomics, Hangzhou Diagens Biotechnology to Commercialize Cytogenetic Workflow for Reproductive Health MT
Bionano Genomics, Inc. and Hangzhou Diagens Biotechnology Co., Ltd. Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis That Combines OGM and Artificial Intelligence CI
Bionano Announces Publication Showing That Ogm Identifies Genetic Aberrations in Sarcoma Samples That May Lead to Improved Diagnosis But Were Missed by Classical Cytogenetics CI
Bionano Genomics, Inc. Announces Nine Poster Presentations and Introduces New High Throughput Stratys System at American Association for Cancer Research Annual Meeting CI
Bionano Genomics, Inc. Announces Publication of Breast Cancer Study Showing the Number of SVs Detected with OGM May be Related to Prognosis, Tumor Progression and Chemotherapy Resistance CI
Scotiabank Trims Price Target on Bionano Genomics to $6 From $7, Maintains Sector Outperform Rating MT
Bionano Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Bionano Genomics, Inc., Q4 2023 Earnings Call, Mar 05, 2024
Bionano Genomics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Bionano Genomics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 CI
Bionano Genomics, Inc. announced that it has received $35 million in funding CI
Bionano Genomics, Inc. Announces Publication of A Study That Applied Ogm to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer CI
Bionano Announces Full Commercial Release of the Stratys?? System for High Throughput Optical Genome Mapping CI
Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care in Genetic Disease Testing CI
Bionano Genomics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 CI
Bionano Announces Significant Upgrades to Its Bionano Solve Pipeline and Its Via? Software for Ogm Data Analysis in Constitution Genetic Disease Research CI
Bionano Genomics, Inc. Announces Publication of Largest Prospective Prenatal Study Comparing Ogm to Chromosomal Microarray Analysis and Karyotyping CI
North American Morning Briefing : Caution -2- DJ
Transcript : Bionano Genomics, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Bionano Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Bionano Genomics, Inc. Reports Goodwill Impairment for the Three Months Ended September 30, 2023 CI
Bionano Genomics, Inc. Reiterates Revenue Guidance for the Full Year 2023 CI
Maxim Group Adjusts Bionano Genomics Price Target to $6 From $30, Maintains Buy Rating MT
Bionano Genomics Expects $80 Million in Gross Proceeds From Registered Offering, Private Placement MT
Bionano Genomics, Inc. Revises Revenue Guidance for the Third Quarter Ended September 30, 2023 CI
Chart Bionano Genomics, Inc.
More charts
Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.75 USD
Average target price
6.667 USD
Spread / Average Target
+788.89%
Consensus
  1. Stock Market
  2. Equities
  3. BNGO Stock
  4. News Bionano Genomics, Inc.
  5. Sector Update: Health Care Stocks Rally Premarket Friday